BeyondSpring Inc. (NASDAQ: BYSI) (“BeyondSpring” or the “Company”), a clinical-stage global biopharmaceutical company focused on developing cancer therapies, today announces that it will have a poster ...

An oral presentation at ASCO & EHA Congress from the CARTITUDE-1 study highlighting heavily pre-treated patients that remain alive and progression-free for more than 5 years after a single CARVYKTI® ...

Title: Long-Term Prophylactic Treatment With Oral Deucrictibant Improves Health-Related Quality of Life and Disease Control in Participants With Hereditary Angioedema: CHAPTER-1 Open-Label Extension ...

From scholarly lectures to TED-style talks, from academic posters to interactive workshops ... and societal spheres. Here is a small sample of their recent work, showcasing the breadth and depth of ...

The poster presentation, based on a post-hoc analysis of the 96-week ... For example, qFibrosis® analysis of Week 96 biopsy samples from 50mg EFX patients (N=26) revealed consistency between ...

The poster presentation, based on a post-hoc analysis ... For example, qFibrosis® analysis of Week 96 biopsy samples from 50mg EFX patients (N=26) revealed consistency between conventional ...

The max poster file size is 6MB. Presentations should incorporate illustrative materials such as tables, graphs, photographs, and large-print text. All submitted posters will be reviewed, and ...

TP53 mutations are a critical biomarker in hematolymphoid malignancies. P53 immunohistochemistry (IHC) is routinely used in clinical laboratories to rapidly screen tumor samples for TP53 gene ...